Resources

We are excited to welcome the newly elected members of the BIA Board of Directors, who will bring fresh insights and expertise to help drive our mission forward. Nick Gardiner shares his perspective on the importance of these appointments and the unique value each new Director brings to the BIA.

Logical Biological, a leading provider of biological critical materials for diagnostics, therapeutic research, and IVD reagent manufacture, has settled into larger, upgraded laboratory space at Discovery Park, marking its third move within the science and innovation campus.

In response to the global rise in demand for innovative therapies, the development and production of novel biopharmaceuticals continue to expand.

BioPartner UK announces the appointment of Mike Fisher, PhD, VP and Head of Business Development at Oncimmune, to its Advisory Board.

The first Budget of the new government will be presented this Wednesday. It’s an important moment, not just for life sciences but for the broader UK economy. Read this blog for an update on the Life Sciences Council, and the launch of our latest Influencing and shaping our sector report.

Read the latest antibody industry report which report which aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September). Besides PiaSky, Vyloy, Imdelltra, Tribuvia, and ivonescimab, five more novel antibody drugs have been approved this year.

Kadans Science Partner today announces that it has broken ground on its new purpose-built laboratory facilities at Merlin Place, Cambridge.

Astex Pharmaceuticals announced today that it will make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, 23rd-25th October 2024, Barcelona, Spain.

Attending the BIA’s TechBio UK conference this year offered an incredible opportunity to witness the ingenuity and innovation driving the future of life sciences.

Landmark studies represent the largest investigational trials to be conducted to date for cannabinoids as a treatment for refractory epilepsy.

Ikarovec’s seed round extension raises funds to continue advanced pre-clinical trials of novel gene therapies to treat blindness and major chronic eye disease.

Ten entrepreneurial life science and technology businesses have begun the immersive Discovery Spark programme at Discovery Park in Kent.

Optibrium today announced the publication of a peer-reviewed study in the Journal of Computer-Aided Molecular Design

The Innovation in Life Sciences funding call seeks applications from organisations in the life sciences sector to create HNCDI projects that apply emerging digital technologies to industrially relevant and impactful research and innovation to further drug discovery and precision medicine in the UK.

Laverock Therapeutics today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.

Read today's blog to learn about our latest reports, upcoming events and our CEO's thoughts on the upcoming budget.

The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.

The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.

This is part of a series of blogs focussing on hearing therapeutics from different sector perspectives. In this blog, Karen Steel shares her thoughts on what she perceives to be some of the biggest opportunities in relation to the development of new treatments for hearing loss.